Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2025-08-07 00:00:00 ET · period of report 2025-08-06 · accession 0000875320-25-000220 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-08-07 | 2025-08-06 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | P - Purchase | $389.58 | +10.0K | 116.0K | +9% | +$3.90M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-08-06 | P | A | 4,290 | $389.08 | 110,258 | D | — | — | (F2) Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. (F1) Open market purchases reported on this line occurred at a weighted average price of $389.08 (range $388.71 to $389.43). |
| 2 | Common | Common Stock | 2025-08-06 | P | A | 5,710 | $389.95 | 115,968 | D | — | — | (F2) Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. (F3) Open market purchases reported on this line occurred at a weighted average price of $389.95 (range $389.72 to $390.53). |